To investigate the effects of caffeine on psychomotor vigilance and sleepiness during sleep restriction and following subsequent recovery sleep. Methods: Participants were N = 48 healthy good sleepers. All participants underwent five nights of sleep satiation (time-in-bed [TIB]: 10 hours), followed by five nights of sleep restriction (TIB: 5 hours), and three nights of recovery sleep (TIB: 8 hours) in a sleep laboratory. Caffeine (200 mg) or placebo was administered in the form of chewing gum at 08:00 am and 12:00 pm each day during the sleep restriction phase. Participants completed hourly 10-minute psychomotor vigilance tests and a modified Maintenance of Wakefulness Test approximately every 4 hours during the sleep restriction and recovery phases. Results: Caffeine maintained objective alertness compared to placebo across the first 3 days of sleep restriction, but this effect was no longer evident by the fourth day. A similar pattern of results was found for Maintenance of Wakefulness Test sleep latencies, such that those in the caffeine group (compared to placebo) did not show maintenance of wakefulness relative to baseline after the second night of restriction. Compared to placebo, participants in the caffeine condition displayed slower return to baseline in alertness and wakefulness across the recovery sleep period. Finally, the caffeine group showed greater N3 sleep duration during recovery.
INTRODUCTION
Caffeine is the most widely used stimulant substance in the world. 1 It is an adenosine receptor antagonist 2 that is often consumed (e.g., in operational settings) to counter the effects of sleep loss and maintain alertness and performance. In the United States, 85% of adults aged 18-24 years consume at least one caffeinated beverage per day, and the amount of caffeine consumed tends to steadily increase with age. 3 Caffeine consumption rates may be even higher for occupations (e.g., physicians, 4 truck drivers, 5 and military service members 6 ) for which sustained performance is required under nonoptimal work/rest schedules.
The efficacy of caffeine as a sleepiness countermeasure is well-established (for review see Roehrs et al. 7 ). A myriad of laboratory studies has consistently shown that caffeine effectively mitigates the alertness-and performance-decrementing effects (e.g., as measured on the Psychomotor Vigilance Test [PVT]-a simple visual reaction time task) across one 8, 9 or two 9-12 nights of total sleep deprivation. Similarly, caffeine has also been shown to effectively sustain performance during sleep deprivation on tasks requiring higher-order cognitive functions, including driving simulation, 13 working memory, 9 and decision-making/ risk-taking. 14 Similar effects have been observed on objective measures of sleepiness (polysomnography [PSG] ) during or at the end of sleep deprivation: For example, caffeine increases daytime sleep latencies compared to placebo. 11, 12 However, the impact of caffeine on measures of self-reported sleepiness are less clear, with some studies reporting only marginal effects on self-reported ratings of sleepiness, 11, 12 although others show a robust effect. 15, 16 A recent study by Paech et al. 9 clearly demonstrates the divergence between self-reported and objective effects of caffeine, with ratings of self-reported sleepiness remaining low only during the first night of sleep deprivation while objective measures of vigilance continued to be maintained into the second night of sleep deprivation.
Although the effects of caffeine during total sleep deprivation are well-documented and well-understood, there have been relatively few studies of its effects across multiple days of sleep restriction-even though chronic sleep restriction is much more common than acute, total sleep deprivation. 17 In fact, previous studies on the effects of caffeine during sleep restriction have generally been limited to one or two nights (one exception is a forced desynchrony study of low dose caffeine over 25 days of 28.57-hour wake episodes followed by 14.28-hour sleep episodes that showed similar performance enhancements to total sleep deprivation studies but a decrease in self-reported sleepiness 18 ). Findings from these short-term sleep restriction studies have consistently mirrored those from total sleep deprivation studies-that is, revealing that caffeine effectively sustains performance and alertness. [19] [20] [21] Accordingly, the primary purpose of the present study was to determine the extent to which the effectiveness of caffeine is maintained over five consecutive days/nights of moderate sleep restriction-a level and duration of sleep restriction previously shown to result in the daily accrual of sleepiness and performance deficits. 22 A second purpose was to determine whether the present 5-day caffeine dosing regimen during sleep restriction would affect subsequent behavioral outcomes and sleep during recovery. Findings from prior studies suggest that caffeine has no impact on recovery following acute, total sleep deprivation 10, 11, 23 unless that recovery sleep is initiated shortly after caffeine administration, which results in reduced total sleep time (TST), increased light (stage 1) sleep, and reduced deep (stage 3) sleep. [23] [24] [25] These effects are comparable to those of caffeine on normal sleep (e.g., following ~16 hours of daytime wakefulness). [26] [27] [28] [29] As these studies have only examined one night of sleep and next day recovery directly after caffeine administration, it is not known if caffeine's deleterious effects on sleep could accumulate across multiple nights of sleep. We hypothesized that chronic caffeine administration coupled with multiple nights of restricted sleep in the present study would negatively impact recovery sleep and behavior.
To date, there have been no studies conducted for the express purpose of determining the effects of caffeine on psychomotor vigilance and sleepiness across multiple days of sleep restriction and subsequent recovery. In the current study, we address this gap, utilizing a study design that simulates a busy work weekalbeit a work week in which sleep is restricted to 5 hours per night-and utilizing a level of caffeine administration (400 mg per day: 200 mg at 08:00 am and 12:00 pm, respectively) that is within the range considered to be "moderate" daily use.
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METHODS
This study was approved by the Walter Reed Army Institute of Research Institutional Review Board. Participants Healthy civilian and active-duty military men and women aged 18 to 39 years (inclusive) were recruited via an advertisement distributed to local universities and military installations. After providing informed consent and completing eligibility questionnaires, participants underwent a physical exam as well as an evaluation of blood and urine samples to determine general health, including pregnancy and drug use. In order to reduce intersubject variability related to sleep habits, individuals were excluded from the study if they reported the following: (1) habitual nightly sleep amounts outside of 6-9 hours, (2) nighttime lights-out times earlier than 09:00 pm on average during weeknights, (3) morning wake-up times later than 09:00 am on average during weekdays, (4) habitual napping (>1 time a week in conjunction with normal sleep habits), and/or (5) a score lower than 31 and higher than 69 on the Morningness-Eveningness Questionnaire. 30 To reduce variability in stimulant use and metabolism, individuals were excluded from the study if they reported caffeine use in excess of 400 mg per day on average and/or regular nicotine use (defined as more than one cigarette or equivalent per week) or if they had a body mass index of 30 or greater (classified as "obese"). Participants were also excluded if they had previously been diagnosed with any cardiovascular, pulmonary, neurological, kidney, liver, or psychiatric diseases and/or if they scored higher than 14 on the Beck Depression Inventory 31 or higher than 41 on the Spielberger Trait Anxiety Inventory. 32 After eligibility was determined, participants were assigned to one of two groups: caffeine or placebo. Demographic variables for the two groups can be found in Table 1 .
Testing Facilities
During sleep satiation, baseline (BL), restriction, and recovery periods, each participant slept in their own sound-attenuated 8' × 10' room. Testing was completed in a designated testing area. When not engaged in testing or sleep, participants remained in a common living area to read, eat, play games, or watch television and movies. Lighting was set at <50 lux during waking hours so as to minimize the impact of light on circadian rhythms.
Intervention
Participants were assigned to either receive caffeine or placebo gum twice a day (at 08:00 am and 12:00 pm) during the 5 days of the restriction period of the study. Gum administration times were selected to most closely approximate caffeine dosing in a typical "work week" and to minimize the impact of caffeine on nighttime sleep (i.e., sleep times during the restriction period were 14 hours removed from the last gum administration). Assignments were done pseudorandomly, that is, the treatment group was randomly chosen and all participants within a session were assigned to that group until reaching 24 participants per group. This particular gum (Military Energy chewing gum, MarketRight Inc., Plano, IL) has been well studied in the laboratory setting.. 9, 14, 33 Participants were given two pieces of gum (either 100 mg caffeine per piece or the same identical gum without the caffeine) to chew for 10 minutes and then discard. Chewing was monitored by study staff to ensure adherence and uniformity of administration at all times. Market research from the original manufacturer of the gum (Amurol Confectioners) indicates that while 85% of the caffeine is released from the gum following 5 minutes of chewing, 99% is released following 10 minutes of chewing. 34 Treatment group assignment was double-blinded, that is, neither the study administrators nor the participants knew the treatment group to which the participant had been assigned.
Study Design
Participants underwent a 14-day protocol which included a fivenight satiation period (nights only in testing facility), followed by a 8.5 day/8 night period held entirely in the testing facility consisting of a BL period (1 day), a restriction period (5 days/5 nights), and a recovery period (2.5 days/3 nights) ( Figure 1 ).
Satiation Period
Participants conducted their normal daily activities (with the exception of using caffeine and alcohol) and returned to the testing facilities at night to sleep for five nights. Time-in-bed (TIB) was 10 hours (09:00 pm-07:00 am) in order to standardize all participants. No measurements other than nighttime PSG and daytime actigraphy were collected during this period. Therefore, no data from this period are presented here, with the exception of the means and standard deviations of the PSG variables during the last night of satiation (Supplemental Table 1 ); these data suggest the sleep satiation period was successful.
Baseline Period
Immediately subsequent to the final night of sleep satiation, participants began the continuous in-laboratory phase of the experiment, which included hourly testing during waking hours. During the BL day, no caffeine was administered.
Restriction Period
Participants then entered a 5 day/5 night period of restricted sleep where TIB was limited to 5 hours (02:00 am-07:00 am). Additionally, participants received either caffeine or placebo at 08:00 am and 12:00 pm each day. At the end of the final day of the restriction period, participants went to bed at 11:00 pm, beginning the recovery period.
Recovery Period
The recovery period lasted for 2.5 days and 3 nights. Hourly testing continued as during the BL and restriction periods. Participants were in bed for 8 hours each night (11:00 pm-07:00 am). On the final day of recovery, participants were released from the testing facility at 06:00 pm.
Measurements
Psychomotor Vigilance Test A 10-minute visual computer-based PVT was administered every hour during the BL, restriction, and recovery periods when the participants were awake. This resulted in 145 individual PVT results for each participant. PVT results were analyzed for speed (1/reaction time × 1000) and number of lapses (reaction times ≥ 500 ms).
Modified Maintenance of Wakefulness Test-Objective Sleepiness
For the Modified Maintenance of Wakefulness Test (mMWT), participants were allowed to lie down in their individual rooms in the dark and were instructed to close their eyes and try to remain awake (this differs from a traditional MWT where the participant is propped up in dim light). The mMWT was terminated at 20 minutes or when the participant reached N1 sleep. This test was given every 2 hours starting at 09:00 am until 03:00 pm. Two additional tests were administered during the nights of sleep restriction (one at 11:00 pm and one at 01:00 am). There were 46 individual mMWT records for each participant.
Stanford Sleepiness Scale-Self-Reported Sleepiness Participants selected which of seven statements best described their current state of alertness ranging from "1-Feeling very alert, wide awake, and energetic" to "7-Very sleepy and cannot stay awake much longer." 35 The Stanford Sleepiness Scale (SSS) was given every hour while awake, and there were 145 individual SSS results for each participant.
Nighttime Polysomnography
During every night of the experiment (Satiation PeriodRecovery Period), participants' sleep was monitored with a standard 13-lead electrode PSG setup; recorded parameters included six electroencephalography channels (Fpz for the ground, F3, F4, C3, C4, O1, O2, and M1 and M2 for the references), two electro-oculography channels (outer canthi of left and right eyes), two electromyography channels (mental and submental), as well as a three-lead electrocardiogram. PSG was recorded with Philips/Respironics Alice 5 equipment and Alice 2.8 software (Respironics, Murrysville, PA) in 30-second epoch intervals. These records were then visually scored from the time of "lights off " to the time of "lights on" by trained technicians according to American Academy of Sleep Medicine guidelines. 36 Variables included in the present analyses consist of: TST; total duration; and latency for stages N1, N2, N3, and rapid eye movement sleep (REM). Data were prepared for analysis by creating a measure to calculate the change in sleep from the last night of sleep satiation, therefore capturing changes from fully satiated sleep. This measure was calculated for each study night (BL, SR1, SR2, SR3, SR4, SR5, R1, R2) by subtracting the variable from the last night of sleep satiation. One participant from the placebo group was excluded from all nighttime polysomnography (NT PSG) analyses due to poor data quality.
Data Analysis
Analyses were performed using linear mixed effects models with random intercepts and slopes. A preliminary omnibus analysis included all study days (i.e., BL, SR1, SR2, SR3, SR4, SR5, R1, R2, and R3). All day-time measures (e.g., PVT, mMWT, and SSS) showed a significant interaction between group and day (Supplementary Table 2 ), therefore, a primary analysis was conducted separately for Sleep Restriction and Recovery. For Sleep Restriction, the level 1 variable was DAY (BL, SR1, SR2, SR3, SR4, SR5). The level 2 variable was GROUP (caffeine, placebo). For Sleep Recovery models, the level 1 variable was DAY (BL, R1, R2, R3). The level 2 variable was GROUP (caffeine, placebo). For all models, we first examined main and interaction effects for DAY and GROUP for PVT speed, PVT lapses, MWT sleep latencies, and SSS scores. These analyses allowed us to determine whether rates of change from BL values during restriction and recovery phases differed significantly across the GROUP variable. Following statistically significant DAY × GROUP effects, we conducted a series of single-df simple interaction contrasts to test GROUP differences in BL -to-"target day" slopes. For example, to examine whether the caffeine group maintained PVT speed on SR1 versus BL compared to the placebo group, we tested a GROUP × DAY (BL, SR1) simple interaction. A statistically significant effect indicates that slopes from BL differ significantly across GROUP. For NT PSG data, only the preliminary omnibus analysis was used, as these data were represented as changes from the last night of sleep satiation, and data from only seven nights were analyzed (nights of BL-R2). As the measure already included changes from BL, post hoc pairwise comparisons were conducted to assess differences between the two groups for each study night. All analyses were performed using SPSS (Version 22; SPSS Inc., Chicago, IL). All variance is expressed as standard error unless noted otherwise.
RESULTS
Demographics
The demographics for the two treatment groups are listed in Table 1 (mean and SD). A two-tailed t-test revealed that the two treatments groups were not significantly different on any demographic variable (p-values can be found in the far right column).
Day-Time Measures
All sleep restriction model results can be found in Table 2 , sleep recovery model results in Table 3 . Only GROUP or DAY × GROUP effects are discussed below.
Psychomotor Vigilance Test: Speed
Consistent with our predictions for sleep restriction, there was a statistically significant DAY × GROUP effect (b = 0.04, SE = 0.01, t = 6.39, p < .001), such that individuals in the caffeine condition performed better than those in the placebo group (Figure 2A) . Simple DAY × GROUP effects emerged for BL-to-SR1 (t = −7.02, p < .001), -SR2 (t = −5.65, p < .001), and -SR3 (t = −2.51, p = .01), suggesting steeper negative slopes in PVT speed relative to BL for participants in the placebo versus the caffeine condition. DAY × GROUP effects were not observed for BL-to-SR4 (p > .05). The DAY × GROUP effect was statistically significant for BL-to-SR5 (t = 9.42, p = .002), such that PVT speed slopes were steeper relative to BL on final day of sleep restriction for the caffeine group compared to the placebo group.
For the sleep recovery model, the DAY × GROUP effect was statistically significant (b = 0.02, SE = 0.004, t = 5.16, p < .001). As shown in Figure 3A , the caffeine group showed a retarded recovery slope compared to the placebo group. Simple DAY × GROUP effects emerged for BL-to-R1 (t = 4.31, p < .001), -R2 (t = 4.06, p < .001), and -R3 (t = 3.46, p = .001), suggesting a delayed recovery slope relative to BL for each day of recovery sleep for those in the caffeine group.
Psychomotor Vigilance Test (PVT): Number of Lapses (≥500 ms)
For the sleep restriction model, the DAY × GROUP effect was statistically significant (b = −0.54, SE = 0.10, t = −5.60, p < .001). As can be seen in Figure 2B , the slope for lapses was significantly stronger for the placebo versus the caffeine group, overall. However, closer inspection of the data using simple DAY × GROUP comparisons revealed a reversal of GROUP differences in slopes for PVT lapses after the third night of sleep restriction. Specifically, the DAY × GROUP effects were statistically significant for BL-SR1 (t = 4.31, p < .001) and -SR2 (t = 4.06, p < .001); no DAY × GROUP effects were observed for BL-to-SR3 (t = 0.42, p = .68). The DAY × GROUP effects were also significant for BL-to-SR4 (t = −2.17, p = .03) and -SR5 (t = −2.89, p = .004), such that the slope for PVT lapses was larger for the caffeine than the placebo group, indicating greater sleep loss-related attentional lapses for those in the caffeine group following the fourth and fifth nights of restricted sleep.
For the recovery sleep model, the pattern of results for PVT lapses mirrored those of PVT speed. There was a significant DAY × GROUP effect (b = −0.32, SE = 0.06, t = −5.17, p < .001), such that the caffeine group had more lapses relative to BL across sleep recovery days than the placebo group ( Figure 3B ). Simple DAY × GROUP effects were statistically significant for BL-to-R1 (t = −4.29, p < .001), -R2 (t = −4.75, p < .001), and -R3 (t = −3.99, p < .001).
Modified Maintenance of Wakefulness Test
For the sleep restriction model, the DAY × GROUP effect was statistically significant (b = 0.42, SE = 0.16, t = 2.57, p = .01). Overall, participants in the caffeine group demonstrated longer MWT sleep latencies across the sleep restriction period than those in the placebo group ( Figure 2C ). However, simple DAY × GROUP comparisons revealed statistically significant effects only for BL-to-SR1 (t = −3.88, p < .001) and -SR2 (t = −2.96, p = .003). Beginning on SR3, DAY × GROUP effects were not statistically significant (p > .05), suggesting no differences in rate of change in MWT sleep latencies across caffeine and placebo groups after the third night of sleep restriction.
For the sleep recovery model, a statistically significant DAY × GROUP effect emerged, such that the rate of change relative to BL was stronger in the placebo versus the caffeine group (b = 0.54, SE = 0.10, t = 5.14, p < .001). As shown in Figure 3C , participants in the caffeine group maintained shorter MWT latencies relative to BL than those in the placebo group. Simple DAY × GROUP interactions were statistically significant for BL-to-R1 (t = 2.65, p = .01), -R2 (t = 5.40, p < .001), and -R3 (t = 3.52, p < .001).
Stanford Sleepiness Scale
For the sleep restriction model, there was no evidence for GROUP or DAY × GROUP effects. However, SSS scores increased across the sleep restriction days, but there was not a differential rate of change between caffeine or placebo group participants' SSS scores ( Figure 2D ).
For the sleep recovery model, there were significant DAY × GROUP effects (b = −0.05, SE = 0.01, t = −4.00, p < .001), such that the caffeine group showed a less robust rate of return to BL SSS scores than the placebo group. Simple DAY × GROUP interactions were statistically significant for BL-to-R1 (t = −4.36, p < .001) and -R2 (t = −4.30, p < .001) but not for BL-to-R3 (t = −1.39, p < .001) ( Figure 3D ).
Nighttime Measures
Statistical values reported here only include significant betweengroup results, that is, significant interactions between group and study day or significant main effects of group. These results were only calculated for the omnibus analysis which included all study day nights (nights of BL-R2). for N3 Duration and REM Duration. There was a significant interaction between group and study day for both N3 Duration (b = 3.07, SE = 0.86, t = 3.57, p < .001) and (REM Duration: b = −3.10, SE = 1.12, t = −2.78, p = .01) (Supplementary Table 3 ). The caffeine group obtained more N3 sleep than the placebo group on the second night of recovery sleep, indicating that the placebo group had returned to satiated sleep levels of N3 while the caffeine group had not (23.42 ± 5.70 vs. 2.37 ± 5.82 minutes from satiated sleep; Figure 4) . The group by day interaction effect for REM Duration was driven by the caffeine group obtaining less REM than the placebo group early in the sleep restriction period. There was also a main effect of GROUP for N3 Duration (b = −24.84, SE = 10.53, t = −2.36, p = .02) and REM Duration (b = 51.90, SE = 14.91, t = 3.48, p < .001), such that over both restriction and recovery nights the caffeine group obtained more N3 sleep and less REM sleep compared to the placebo group (19.51 ± 2.02 vs. 15.18 ± 2.06 minutes from satiated sleep for N3; 28.82 ± 2.95 vs. 51.10 ± 3.00 minutes from satiated sleep for REM).
Nighttime Polysomnography
DISCUSSION
Although daily administration of caffeine 400 mg (200 mg at 08:00 am and 12:00 pm) helped to maintain BL levels of alertness and performance across the first 3 days of sleep restriction (5 hours per night), this dosing regimen was no longer effective by the fourth day of sleep restriction as a sleep restriction-based tolerance to caffeine developed. Based on prior findings, it was expected that significant sleepiness would accrue across multiple, consecutive days of sleep restriction and decrease the alerting properties of caffeine (e.g., see 22, 37 ), but the failure of the caffeine dosing regimen to more effectively offset this accruing sleep pressure was unexpected, since caffeine has been repeatedly shown to significantly enhance performance and objective alertness compared to placebo, even after 2 days of total sleep deprivation.
However, it was not unexpected to find that recovery was relatively impaired in the caffeine group-that is, this group fell asleep significantly faster on the modified MWT and was slower to return to BL on all measures during the recovery period compared to the placebo group. Caffeine also resulted in an increased amount of N3 sleep on the second night of recovery sleep (i.e., the night following the first day of no caffeine administration), indicating a greater homeostatic sleep need.
A few key elements of this study are likely impacting adenosine: the presence or absence of caffeine, the repeated chronic administration of caffeine, and the accumulation of sleep restriction over 5 days. The pattern of the present results and these key elements suggest at least two nonmutually exclusive possibilities: (1) Chronic administration of caffeine across the sleep restriction period may have resulted in the utilization of cognitive/alertness-sustaining resources at a faster rate than placebo-essentially resulting in a greater level of sleep debt by the end of the 5-day sleep restriction period. This possibility is consistent with both the NT PSG findings (which suggest relatively increased sleep pressure; and the daytime measures that likewise reveal a relatively increased level of lingering sleepiness in the caffeine group). (2) Administration of caffeine across the 5 days of sleep restriction may have altered the extracellular adenosine/adenosine receptor density ratio in a manner that lengthens the process by which recovery from sleep loss is affected (consistent with the "adenosine hypothesis" 38, 39 ). These two possibilities in conjunction suggest a doubly negative impact of caffeine combined with sleep restriction, where it speeds up the accumulation of sleep debt and slows down the process of recovery.
That is, as shown previously by Porkka-Heiskanen et al. 40 , acute sleep deprivation results in acutely increased levels of extracellular adenosine (which inhibits neuronal action potentials and promotes sleep) in the basal forebrain of rats. However, with continued (extended) disruption of sleep (e.g., shortening and/or fragmenting sleep), the levels of extracellular adenosine wane. 41, 42 This is accompanied by complementary upregulation of adenosine receptors, which, it is hypothesized, serves to sustain elevated sleep pressure. This hypothesis has been invoked to explain the observation that recovery from several days of sleep restriction takes longer (more nights of sleep required) than does recovery from a comparable number of hours lost via acute sleep deprivation (see Belenky et al. 22 )-that is, normal extracellular adenosine levels are restored relatively quickly during recovery sleep, but the subsequent downregulation of adenosine receptors to normal levels requires several days. Thus, recovery from acute total sleep deprivation is relatively rapid because it occurs over a relatively brief period-not enough time to produce waning levels of extracellular adenosine and/or upregulation of adenosine receptors. In contrast, several days of sleep restriction (as in the present study) would putatively result in waning levels of extracellular adenosine and complementary upregulation of adenosine receptors. And while the normal levels of extracellular adenosine are rapidly restored during recovery sleep following sleep restriction, it could take several days before downregulation restores adenosine receptor density to its normal level-which manifests as several days of continued above-normal levels of sleepiness.
Thus, it is possible that in the present study caffeine administration itself had an effect on adenosine receptor density, resulting in a greater upregulation of adenosine receptors than that produced by sleep restriction alone-and this accounts for the group differences in both the nighttime sleep and daytime alertness and performance measures found during the recovery phase of the present study. This possibility is bolstered by the finding that caffeine administration results in upregulation of adenosine receptors in animals. 43 For this particular sleep restriction paradigm, caffeine was shown to increase stage 3 sleep during recovery but only on the first night following a day with no caffeine. This is important because many studies have found that caffeine can decrease slow wave sleep when the sleep occurs directly following a day where caffeine was administered. 44 Perhaps in this case, only in the absence of caffeine could the cost of chronic caffeine use be seen in deep sleep. This, taken with the increased objective daytime sleepiness and slowed return to BL on all daytime measures, is consistent with the possibility that there is a physiological cost associated with the use of caffeine during sleep restriction.
A limitation of this study is that the same dose of caffeine was given each day. In real-life situations, caffeine is more likely to be consumed on an as-needed basis. It is possible that increasing doses and/or altering the timing and number of caffeine administrations would have successfully sustained alertness and performance over the entire 5-day sleep restriction period. In fact, a 25-day forced desynchony study (28.57 hours wake, 14.28 hours sleep) showed that while continuous low-dose caffeine helped participants maintain performance throughout the multiweek study, it also increased self-reported sleepiness score above placebo. 18 Future work should continue to explore the trade-offs of caffeine dosage and timing with sustained sleep restriction.
An additional limitation of this study is that the recovery period was only for 8 hours a night. This may have resulted in only partial recovery from the sleep restriction period and it may have impacted our daytime measures. Therefore, we presently do not know if more recovery sleep could potentially offset the delay in recovery seen for caffeine. Another potential limitation of our recovery period is that the last mMWT of the recovery period was administered at 03:00 pm. Therefore, the impact of caffeine on objective sleepiness during recovery at night time is still unknown.
In conclusion, this is the first study to provide evidence that the same daily dose of caffeine loses efficacy across multiple days/nights of sleep restriction; and that caffeine administration during sleep restriction negatively impacts subsequent recovery processes. This work has implications regarding the judicious use of caffeine in operational and nonoperational environments. In particular, and as topics for future investigation, the present findings suggest some interesting possibilities: (1) Does sleep banking 45 exert its positive effects on alertness and performance via downregulation of adenosine receptors to super-low density levels? If so, use of caffeine during the sleep extension phase would be expected to reduce or block the effectiveness of sleep banking. (2) If recovery from sleep restriction involves downregulation of adenosine receptors, would such recovery be reduced or delayed by administration of daytime caffeine during this phase? (3) Would either delaying the start or advancing the end of administration of caffeine by a day or two during restriction accelerate recovery? And if so, how does that benefit balance with potential performance declines without caffeine during restriction?
